-
Recent Posts
- Dementia Prevalence Calculator and Supporting Toolset (NHS England)
- EU ALCOVE Project: Latest Reports (ALCOVE Official Website / University of Worcester’s Association for Dementia Studies)
- Wolverhampton’s Joint Dementia Strategy (Dementia Action Alliance / Wolverhampton City Council / Wolverhampton City Primary Care Trust)
- Dementia Innovation Challenge Prizes (NHS Institute for Innovation and Improvement)
- G8 Dementia Summit to Coordinate Global Efforts on Dementia Research (Department of Health)
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Evidence
- NICE Guidelines
- NIHR
- NIHRSDO
- Patients Association
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Tag Archives: Novartis)
Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (Health Technology Assessment)
[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The purpose of this Health Technology Assessment was to review and update guidance to the NHS in England and Wales … Continue reading
Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Researchers (mostly), Management of Condition, National, NHS, NIHR, Pharmacological Treatments, Systematic Reviews, UK
Tagged Acetylcholinesterase Inhibitors (AChEIs), AChEIs, Activities of Daily Living (ADL) Scale, Activities of Daily Living Scale, Alzheimer's Disease, Aricept, Best Supportive Care (BSC), Donepezil, Ebixa, Economic Evaluation, Eisai Ltd, Exelon, Galantamine, Health Technology Assessment Study, Lundbeck), Markov Model, Memantine, Memantine Hydrochloride, Mini Mental State Examination (MMSE), MMSE: Mini-Mental State Examination, National Institute for Health Research (NIHR), NIHR: National Institute for Health Research, Novartis), Peninsula Technology Assessment Group, QALY, Quality-Adjusted Life-Year (QALY), Reminyl, Rivastigmine, Shire Pharma, Standardized Mini-Mental State Examination: SMMSE, Synergie UK (HTA Department), Technology Assessment Report (TAR), Willingness-to-Pay (WTP)
Leave a comment
Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (NICE)
[A version of this abstract appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 1 Issue 9, April 2011]. Abstract Note: The long-awaited review and re-appraisal of Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer’s Disease has resulted in changes to … Continue reading
Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, Management of Condition, National, NICE Guidelines, Pharmacological Treatments, Practical Advice, Systematic Reviews, Universal Interest
Tagged AChE Inhibitors, Donepezil, Donepezil (Aricept, Drugs for Treatment of Alzheimer’s Disease, Eisai/Pfizer), Galantamine, Galantamine (Reminyl, Lundbeck), Memantine, Memantine (Ebixa), NICE, NICE Technology Appraisal Guidance: TA217, Novartis), Rivastigmine, Rivastigmine (Exelon, Shire)
Leave a comment
